Cohen, A, Hove, M.
Physical Health of the Severe and Enduring Mentally Ill. Sainsbury Centre for Mental Health, 2001.
Sebastian, C, Beer, MD. Physical health of psychiatric patients admitted to a low secure challenging behaviour unit. J Psychiatr Intensive Care
2006; 1: 77–83.
Thomson, L, Bogue, J, Humphreys, M, Owens, D, Johnstone, E.
The State Hospital Survey: a description of psychiatric patients in conditions of special security in Scotland. J Forensic Psychiatr
1997; 8: 263–84.
Marder, SR, Essock, SM, Miller, AL, Buchanan, RW, Casey, DE, Davis, JM, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry
2004; 161: 1334–49.
National Institute for Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. NICE, 2002.
Gough, K, Churchward, S, Dorkins, E, Fee, J, Oxborrow, S, Parker, J, et al. Audit of the NICE Guidelines for Schizophrenia in an NHS forensic psychiatric service. Br J Forensic Pract
2007; 9: 28–34.
Singh, R, Ahmed, MJR, Shaffiullha, M.
Audit of monitoring of second generation antipsychotic drugs?
Bulletin of Transcultural Special Interest Group of Royal College of Psychiatrists,
Zhang, Z-J, Yao, Z-J, Liu, W, Fang, Q, Reynolds, GP. Effects of antipsychotics on fat deposition and changes in leptin and Insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry
2004; 184: 58–62.
McCreadie, RG. Diet, smoking and cardiovascular risk in people with schizophrenia. Descriptive study. Br J Psychiatry
2003; 183: 534–9.
Thakore, JH. Metabolic syndrome and schizophrenia. Br J Psychiatry
2005; 186: 455–6.
Haddad, PM. Antipsychotics and diabetes: review of non-prospective data. Br J Psychiatry
2004; 184 (suppl 47): s80–6.
Lambert, T, Chapman, L.
Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust
2004; 181: 544–8.
Petty, RG. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res
1999; 35 (suppl 1): 67–73.
Holt, RIG. The medical causes and consequences of hyperprolactinaemia. A context for psychiatrists. J Psychopharmacol
2008; 22 (suppl 2): 28–37.
Berner, MM, Hagen, M, Kriston, L.
Management of sexual dysfunction due to antipsychotic drug therapy?
Cochrane Database Syst Rev
2007; Issue 3: CD003546.
Herxheimer, A, Healy, D.
Arrhythmias and sudden death in patients taking antipsychotic drugs. BMJ
2002; 325: 1253–4.
Ray, WA, Meador, KG. Antipsychotics and sudden death: is thioridazine the only bad actor?
Br J Psychiatry
2002; 180: 483–4.
Abdelmawla, N, Mitchell, AJ. Sudden cardiac death and antipsychotics. Part 2: Monitoring and prevention. Adv Psychiatr Treat
2006; 12: 100–9.
Haddad, PM, Sharma, SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs
2007; 21: 911–36.
Gill, SS, Rochon, PA, Herrmann, N, Philip, EL, Sykora, K, Gunraj, N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ
2005; 330: 445.
NHS Connecting for Health. NHS Care Record Service. NHS, 2005.
The NHS IT Project: the Biggest Computer Project in the World Ever. Radcliffe Publishing, 2005.
British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary 51. BMA, 2006.
David, T, Paton, C, Kerwin, R.
The Maudsley 2005–2006 Prescribing Guidelines (8th edn). Taylor and Francis, 2005.
Lebovitz, HE. Metabolic consequences of atypical antipsychotic drugs. Psychiatr Q
2003; 74: 277–90.
Metabolic effects associated with atypical antipsychotic medications. Perspect Psychiatr Care
2004; 40: 70–2.
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care
2004: 27: 596–601.
Medicines Control Agency, Committee on Safety of Medicines. QT interval prolongation with antipsychotics. Curr Probl Pharmacovigilance
2001; 27: 4.
Royal College of Psychiatrists. Consensus Statement on High-Dose Antipsychotic Medication
. Royal College of Psychiatrists, 2006.
Maguire, GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry
2002; 63 (suppl 4): 56–62.
Day, JC, Wood, G, Dewey, M, Bentall, RP. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry
1995; 166: 650–3.
The NICE schizophrenia guidelines: the challenge of implementation. Adv Psychiatr Treat
2004; 10: 403–12.